Detection of clinically suspected prostate cancer using ultrasound-guided transrectal biopsy is standard of care .
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
The relatively high probability of missing clinically significant cancers during initial sextant biopsies led to the introduction of extended 10-12 core biopsy and subsequently to 20+ core saturation biopsy strategies [1-9]. Nevertheless, underdiagnosis of high risk prostate cancer even in patients with low PSA levels still occurs in 25-30% [10,11]. Anteriorly located prostate cancer contributes to these high rates and data from magnetic resonance imaging (MRI) studies underlines these considerations [12-14].
Seles M, Gutschi T, Mayrhofer K, Fischereder K, Ehrlich G, Gallé G, Gutschi S, Pachernegg O, Pummer K, Augustin H. Are you the author?
Department of Urology, Medical University of Graz, Austria.
Reference: BJU Int. 2015 Feb 26. Epub ahead of print.